These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20207023)

  • 1. Therapy for persistent HIV.
    Keedy KS; Margolis DM
    Trends Pharmacol Sci; 2010 May; 31(5):206-11. PubMed ID: 20207023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
    Kulkosky J; Pomerantz RJ
    Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can HIV infection be eradicated through use of potent antiviral agents?
    Josefsson L; Dahl V; Palmer S
    Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is it possible to cure HIV infection?].
    Gutiérrez C; Madrid NP; Moreno S
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():54-6. PubMed ID: 26365737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of HIV-1 resistance.
    Paredes R; Clotet B
    Antiviral Res; 2010 Jan; 85(1):245-65. PubMed ID: 19808056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication therapies for HIV Infection: time to begin again.
    Margolis DM
    AIDS Res Hum Retroviruses; 2011 Apr; 27(4):347-53. PubMed ID: 21314240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.
    Turriziani O; Andreoni M; Antonelli G
    Clin Microbiol Infect; 2010 Oct; 16(10):1518-24. PubMed ID: 20673260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for treatment of latent HIV.
    Barton KM; Burch BD; Soriano-Sarabia N; Margolis DM
    Clin Pharmacol Ther; 2013 Jan; 93(1):46-56. PubMed ID: 23212106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-2 down, HIV-1 to go? Understanding the possibilities of treatment as prevention.
    Bruhn CA; Gilbert MT
    Lancet Infect Dis; 2011 Apr; 11(4):260-1. PubMed ID: 21453865
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
    Menéndez-Arias L; Alvarez M
    Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
    Dhamija N; Rawat P; Mitra D
    Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy for HIV: drug resistance and sequencing.
    Burkle WS
    J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status of HIV infection: a review for non-HIV-treating physicians.
    Knoll B; Lassmann B; Temesgen Z
    Int J Dermatol; 2007 Dec; 46(12):1219-28. PubMed ID: 18173512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do resistance patterns vary between different FTC containing drug regimens?
    Chacko L; Chamberlain F; Mandalia S; Nelson M
    J Infect; 2014 May; 68(5):503-5. PubMed ID: 24513393
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug combinations for HIV: what's new?
    Scourfield A; Waters L; Nelson M
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1001-11. PubMed ID: 22029520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concept of structured treatment interruptions in the management of patients with human immunodeficiency virus (HIV) disease: where are we currently?
    Idemyor V
    HIV Clin Trials; 2003; 4(2):79-83. PubMed ID: 12671774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV and drug resistance - interpretation and therapeutic progress.
    Gürtler L
    Intervirology; 2012; 55(2):77-8. PubMed ID: 22286873
    [No Abstract]   [Full Text] [Related]  

  • 20. Scientific considerations for pharmacoenhancers in antiretroviral therapy.
    Arya V; Robertson SM; Struble KA; Murray JS
    J Clin Pharmacol; 2012 Aug; 52(8):1128-33. PubMed ID: 21712496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.